Hanmi Pharma wins South Korea approval for Efpe auto-injector obesity drug
Bitget2026/10/07 09:56South Korea’s MFDS granted marketing authorization for Hanmi Pharmaceutical’s Efpeo Auto-Injector (efpeglenatide), an obesity drug for chronic weight management. Approval covers five strengths; indicated for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Authorization date Oct. 7, 2026; Hanmi targets domestic launch by year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007800667), on October 07, 2026, and is solely responsible for the information contained therein.
- South Korea’s MFDS granted marketing authorization for Hanmi Pharmaceutical’s Efpeo Auto-Injector (efpeglenatide), an obesity drug for chronic weight management.
- Approval covers five strengths; indicated for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity.
- Authorization date Oct. 7, 2026; Hanmi targets domestic launch by year-end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia Acting CEO Kress Reassures the Market: No Customer Loss and No Employee Exodus
Nvidia released its first quarterly financial report since Jensen Huang's resignation, after which Colette Kress told the media that major client demand has not been affected and the workforce remains stable, emphasizing that "everything is business as usual." The company's share price rose over 3% after hours, though the stock is still down 24% for the month.
South Korea's KOSPI Index turns negative after rising more than 3% intraday
A 6% yield is not "extremely cheap"! Fidelity throws cold water: Long-term inflation and debt risks are key, and US Treasuries may no longer serve as a "safe haven" for the stock market.
In the view of Salman Ahmed, Head of Global Macro and Strategic Asset Allocation at Fidelity International, even if the 10-year US Treasury yield rises to 6%, it would not be considered "extremely cheap."

Japan's exports in October rose 20.5% year-on-year, exceeding expectations; semiconductor equipment exports surged nearly 50%.
Official data released by Japan on Wednesday showed that exports in October rose by 20.5% year-on-year, ending a two-month slowdown.
